BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Salvado M, Vargas V, Vidal M, Simon-Talero M, Camacho J, Gamez J. Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient. World J Gastroenterol 2015; 21(36): 10475-10479 [PMID: 26420975 DOI: 10.3748/wjg.v21.i36.10475]
URL: https://www.wjgnet.com/1007-9327/full/v21/i36/10475.htm
Number Citing Articles
1
H Blasco, F Patin, CR Andres, P Corcia, PH Gordon. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotectionExpert Opinion on Pharmacotherapy 2016; 17(12): 1669 doi: 10.1080/14656566.2016.1202919
2
Sebastiano Giuseppe Crisafulli, Simona Brajkovic, Maria Sara Cipolat Mis, Valeria Parente, Stefania Corti. Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral SclerosisMolecular Neurobiology 2018; 55(4): 2789 doi: 10.1007/s12035-017-0532-4
3
Jesus S. Mora, Angela Genge, Adriano Chio, Conrado J. Estol, Delia Chaverri, Maria Hernández, Saúl Marín, Javier Mascias, Gabriel E. Rodriguez, Monica Povedano, Andrés Paipa, Raul Dominguez, Josep Gamez, Maria Salvado, Christian Lunetta, Carlos Ballario, Nilo Riva, Jessica Mandrioli, Alain Moussy, Jean-Pierre Kinet, Christian Auclair, Patrice Dubreuil, Vincent Arnold, Colin D. Mansfield, Olivier Hermine. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trialAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2020; 21(1-2): 5 doi: 10.1080/21678421.2019.1632346
4
Arsh Haj Mohamad Ebrahim Ketabforoush, Rojin Chegini, Shirin Barati, Fatemeh Tahmasebi, Bardia Moghisseh, Mohammad Taghi Joghataei, Faezeh Faghihi, Fereshteh Azedi. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment seriesBiomedicine & Pharmacotherapy 2023; 160: 114378 doi: 10.1016/j.biopha.2023.114378
5
Natalia Papadopoulos, Johan Lennartsson. The PDGF/PDGFR pathway as a drug targetMolecular Aspects of Medicine 2018; 62: 75 doi: 10.1016/j.mam.2017.11.007
6
MasitinibReactions Weekly 2015; 1574(1): 171 doi: 10.1007/s40278-015-1626-2
7
Bethany D. Latham, D. Spencer Oskin, Rachel D. Crouch, Matthew J. Vergne, Klarissa D. Jackson. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor MasitinibChemical Research in Toxicology 2022; 35(9): 1467 doi: 10.1021/acs.chemrestox.2c00057
8
Abdullah Ashraf Hamad, Basma Ehab Amer, Yousef Hawas, Manar Alaa Mabrouk, Mostafa Meshref. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidenceNeurological Sciences 2024; 45(5): 1861 doi: 10.1007/s10072-023-07259-w
9
Sebastian A. Lewandowski, Linda Fredriksson, Daniel A. Lawrence, Ulf Eriksson. Pharmacological targeting of the PDGF-CC signaling pathway for blood–brain barrier restoration in neurological disordersPharmacology & Therapeutics 2016; 167: 108 doi: 10.1016/j.pharmthera.2016.07.016
10
A. O. Bueverov, E. L. Bueverova. Medically-induced autoimmune hepatitis: a rare disease or a rare diagnosis?Dokazatel'naya gastroenterologiya 2017; 6(1): 47 doi: 10.17116/dokgastro20176147-55
11
David E. Kleiner. Recent Advances in the Histopathology of Drug-Induced Liver InjurySurgical Pathology Clinics 2018; 11(2): 297 doi: 10.1016/j.path.2018.02.009
12
Mehdi Brahmi, Philippe A. Cassier. Masitinib for gastrointestinal stromal tumorsExpert Opinion on Orphan Drugs 2016; 4(6): 671 doi: 10.1080/21678707.2016.1180973